iptacopan
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Paroxysmal Nocturnal Hemoglobinuria (PNH) With Signs of Active Hemolysis
Conditions
Paroxysmal Nocturnal Hemoglobinuria (PNH) With Signs of Active Hemolysis
Trial Timeline
Apr 9, 2018 → Feb 28, 2022
NCT ID
NCT03439839About iptacopan
iptacopan is a phase 2 stage product being developed by Novartis for Paroxysmal Nocturnal Hemoglobinuria (PNH) With Signs of Active Hemolysis. The current trial status is completed. This product is registered under clinical trial identifier NCT03439839. Target conditions include Paroxysmal Nocturnal Hemoglobinuria (PNH) With Signs of Active Hemolysis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05222412 | Pre-clinical | Active |
| NCT06994845 | Phase 3 | Recruiting |
| NCT06903234 | Pre-clinical | Active |
| NCT06797518 | Phase 2 | Recruiting |
| NCT06517758 | Phase 3 | Recruiting |
| NCT05935215 | Phase 3 | Recruiting |
| NCT05630001 | Phase 3 | Completed |
| NCT04889430 | Phase 3 | Active |
| NCT05086744 | Phase 2 | Terminated |
| NCT04747613 | Phase 3 | Active |
| NCT03439839 | Phase 2 | Completed |
Competing Products
20 competing products in Paroxysmal Nocturnal Hemoglobinuria (PNH) With Signs of Active Hemolysis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Crovalimab + Eculizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Crovalimab + Placebo | Chugai Pharmaceutical | Phase 1/2 | 41 |
| Crovalimab + Eculizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Ravulizumab | AstraZeneca | Pre-clinical | 23 |
| Eculizumab | AstraZeneca | Phase 3 | 77 |
| Danicopan | AstraZeneca | Phase 3 | 77 |
| LNP023 | Novartis | Pre-clinical | 23 |
| Iptacopan (LNP023) | Novartis | Phase 3 | 77 |
| LNP023 | Novartis | Phase 2 | 52 |
| Iptacopan | Novartis | Pre-clinical | 23 |
| Iptacopan | Novartis | Phase 3 | 77 |
| LNP023 + Eculizumab + Ravulizumab | Novartis | Phase 3 | 77 |
| LNP023 | Novartis | Phase 3 | 77 |
| LFG316 + LNP023 | Novartis | Phase 2 | 52 |
| Iptacopan | Novartis | Phase 3 | 77 |
| Crovalimab | Roche | Phase 3 | 77 |
| ABP 959 + Eculizumab | Amgen | Phase 3 | 76 |
| Pegcetacoplan | Swedish Orphan Biovitrum | Pre-clinical | 22 |
| BMS-919373 + Placebo (Matching with BMS-919373) | Bristol Myers Squibb | Phase 2 | 51 |
| Humanized anti-Factor Bb monoclonal antibody + Placebo | Sanofi | Phase 1 | 32 |